The Regulation Amending the Regulation on Clinical Research of
Pharmaceutical and Biological Products was published in Official
Gazette number 29474 on 13 September 2015 ("Regulation").
Among other changes, the new Regulation removes permit requirements
for clinical research centers, as well as changes requirements for
ethics committee and education processes.
The Regulation makes changes to the Regulation on Clinical
Research of Pharmaceutical and Biological Products (Official
Gazette number 28617, 13 April 2013). Significant provisions
Removing the obligation on clinical research centers to have a
permit to carry out clinical research from the Turkish Drug and
Medical Device Institution.
For applications to conduct multicenter clinical research,
ethics committee approval is required. Approval must be obtained
from the committee located in the coordinating center's region
(or closest committee to the coordinating center, if none exists
within the particular region). If the research is conducted by a
single center, approval must be obtained from the ethics committee
located in the research center's region (or closest regional
committee, if none exists within the particular region).
Extending the deadline to 1 April 2016 for health professionals
and ethics committee members to complete primary education about
good clinical practice and clinical research. The ethics committees
are established by the Regulation on Clinical Research of
Pharmaceutical and Biological Products and approved by the Turkish
Drug and Medical Device Institution.
The Regulation came into effect on 13 September 2015, when it
was announced in the Official Gazette. It is enforced by the
President of the Turkish Drug and Medical Device Institution.
Please see this link for full text of the Regulation (only
available in Turkish).
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
The Turkish Ministry of Health ("Ministry") and Social Security Institute ("Institute") announced that according to a new cost savings action plan, pharmaceuticals imported under named-patient sales will occur through the Institute, rather that the Turkish Pharmacists Association ("Association") from 2 May 2017.
The Turkish Competition Board ("Board") recently published a short form decision concluding that the Turkish Pharmacists Association had abused its dominant market position when procuring pharmaceuticals from abroad by executing exclusivity agreements with pharmaceutical suppliers.
Turkey has amended principles for health-related R&D tenders. The changes apply to procurement of R&D services by the Ministry of Health, within the scope of Article 3(f) of Public Tender Act number 4734.
After studying bioengineering and completing a PhD in the San Francisco Bay Area and a two-year postdoctoral research fellowship in London, Mark has spent the past four years analysing global health policy.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).